神经母细胞瘤患者淋巴细胞激活杀伤细胞（LAK）活性的体外诱导
In vitro induction of lymphokine-activated killer (LAK) activity in patients with neuroblastoma.
作者信息
Handgretinger R, Bruchelt G, Kimmig A, Dopfer R, Niethammer D, Treuner J
机构信息
Children's University Hospital, Department Hematology/Oncology, Tuebingen, FRG.
出版信息
Pediatr Hematol Oncol. 1989;6(4):307-17. doi: 10.3109/08880018909034302.
Therapy of disseminated neuroblastoma remains an unsolved problem in pediatric oncology. Therefore, new therapeutic approaches have to be developed for this malignancy. In this paper, we investigated the possibility of the in vitro generation and expansion of lymphokine-activated killer (LAK) cells in patients with disseminated neuroblastoma. Although the patients had very low Natural Killer (NK) activity, it was possible to induce LAK activity in peripheral mononuclear lymphocytes (PMNC) by incubation with Interleukin-2 (IL-2). Moreover, the PMNCs could be expanded up to 50-fold in the presence of Interleukin-2 while maintaining or even increasing their LAK activity. The target cells were neuroblastoma cell lines and, in one case, autologous neuroblastoma cells. Additionally, it was possible to induce LAK cell activity against autologous neuroblastoma cells in bone marrow-derived mononuclear cells.
播散性神经母细胞瘤的治疗仍是儿科肿瘤学中一个尚未解决的问题。因此，必须为这种恶性肿瘤开发新的治疗方法。在本文中，我们研究了播散性神经母细胞瘤患者体外产生和扩增淋巴因子激活的杀伤（LAK）细胞的可能性。尽管患者的自然杀伤（NK）活性非常低，但通过与白细胞介素-2（IL-2）孵育，有可能在外周血单个核细胞（PMNC）中诱导LAK活性。此外，在白细胞介素-2存在的情况下，PMNC可以扩增至50倍，同时保持甚至增强其LAK活性。靶细胞是神经母细胞瘤细胞系，在一个病例中是自体神经母细胞瘤细胞。此外，在骨髓来源的单个核细胞中也有可能诱导针对自体神经母细胞瘤细胞的LAK细胞活性。
Zotero 插件